|
|
|
|
|
|
|
|
|
|
|
Grants / Funding |
Hal E. Broxmeyer, Ph.D.
Ghalib Alkhatib, Ph.D.
Janice S. Blum, Ph.D.
- National Institutes of Health: NIAID. RO1 AI49589: “MHC Class II-Restricted Cytoplasmic Antigen Presentation” J.S. Blum, Principal Investigator (2001-2007)
- National Institutes of Health: NIAID. PO1 AI0560972-01: “Poxvirus modulation of immune responses” J.S. Blum, Principal Investigator, Project 4/ JS Blum, Program Director and Core A (2001-2008)
- Indiana University – Lilly Endowment (2003-2006)
- Indiana Genomics Initiative. C. Brater, Principal Investigator, J.S. Blum, Co-Investigator
- National Institutes of Health, NIAID. T32 AI060519: “Immunology and Infectious Diseases” J.S. Blum, PI (2004-2009)
H. Scott Boswell, Ph.D.
Randy R. Brutkiewicz, Ph.D.
- National Institutes of Health, National Institute of Allergy and Infectious Diseases, “Poxvirus Modulation of Immune Responses”, PO1 AI056097; Project 3 Leader: Randy R. Brutkiewicz, Ph.D. Principal Investigator: Janice S. Blum, Ph.D.; (9/01/03 – 2/29/08).
- National Institutes of Health, National Institute of Allergy and Infectious Diseases, “Poxvirus Modulation of Immune Responses”, PO1 AI056097; Core B Director: Randy R. Brutkiewicz, Ph.D. Principal Investigator: Janis S. Blum, Ph.D.; (9/01/03 – 2/29/08).
- Lymphoma and Leukemia Society Scholar Award: “Mechanisms of Immune Evasion by Lymphoma and Leukemia Cells”. Principal Investigator: Randy R. Brutkiewicz, Ph.D. (07/01/03 – 06/30/08).
- National Institutes of Health, National Institute of Allergy and Infectious Diseases, “CD1 Molecules and Host Defense”, RO1 AI46455; Principal Investigator: Randy R. Brutkiewicz, Ph.D. (2/1/00 – 3/31/10).
Edward M. Chan, M.D.
- Research Core Pilot Grant, Indiana University School of Medicine (No cost extension) “Genetic Alterations in Leukemia”. PI: Chan: {7/24/02 – present}
- Clarian Values Fund for Research, Clarian Health Partners, “Transcriptional Repression by the AML1-FOG2 Fusion Protein in Myelodysplastic Syndrome” . PI: Chan. (5/1/04 – 10/30/06)
- Young Investigator Award, Department of Veterans Affairs, “Distinct Hematopoietic Effects of the AML1-FOG2 and FOG2-AML1 Fusion Proteins in Myelodysplasia”. PI: Chan. (7/1/05 – present)
- National Institutes of Health (NIA) 1R21AG029137-01, “Genetic Alterations in the Bone Marrow of Elderly Patients with Anemia”. PI: Chan. (12/1/06 – 11/30/08)
- Merit Review Award, Department of Veterans Affairs, “Role of FOG2 in the Pathogenesis of Myelodysplasia”. PI: Chan. (4/1/07 – 3/30/10)
Cheong-Hee Chang, Ph.D.
Yan Chen, Ph.D.
Alexander L. Dent, Ph.D.
- IUSOM Biomedical Research grant, 2006-2007
Xin-Yuan Fu, Ph.D.
Thomas A. Gardner, M.D.
Mark G. Goebl, Ph.D.
Maureen A. Harrington, Ph.D.
Johnny J. He, Ph.D.
Soon-Cheol Hong, Ph.D.
Meei-Huey Jeng, Ph.D.
Chinghai Kao, PhD.
- NIH/NCI 1F31 CA106214 (PI: Jemenez, J. A.) Title: “Soluble Trail armed prostate restricted replicative adenovirus. This is scholarship awarded to an M.D./Ph.D. student, Juan A. Jemenez.
- DOD Prostate Cancer Program W81XWH-04-1-0168 (PI: Kao, C) Title: “PSES-a novel prostate specific chimeric enhancer for prostate cancer gene therapy.”
- NIH/NCI 2RO1 CA074042-07 (PI: Kao, C.) Title: “Tissue Specific Gene Therapy for Human Prostate Cancer.”
Michael J. Klemsz, Ph.D.
Suk-Hee Lee, Ph.D.
Daniela Matei, M.D., Ph.D.
- American Cancer Society: 7/1/05-06/30/10, “The Functional Role of PDGFRαa in Ovarian Carcinoma”
- Clarian Values Fund; 5/1/04-10/31/06, “Markers Of Sensitivity To PDGFR Inhibition In Ovarian Carcinoma In-Vivo” 5/1/04 – 4/31/06. Objectives: This proposal will evaluate translational end-points in human tumor specimens obtained as part of a clinical trial utilizing Imatinib mesylate plus Docetaxel in patients with refractory ovarian carcinoma. Samples obtained from patients enrolled in this clinical trial will be analyzed for activation of the PDGFR pathway.
- Amgen Oncology Institute: 07/01/04-06/30/07, “The Functional Role of PDGFRαa in Ovarian Carcinoma”
Objectives: This proposal will evaluate PDGF regulated signaling in ovarian carcinoma and interaction between PDGFR and HSP90.
- National Cancer Institute (NCI): 12/01/04-12/01/09, Interrogating Epigenetic Changes in Cancer Genomes/ Predicting Drug Resistance in Cancer Genomes by DNA Methylation Profiling. Co-investigator
- IUCC Ovarian Cancer Pilot Project: 6/1/05-12/31/06, “The Functional Role of Transglutaminase 2 in Ovarian Cancer”
- Marsha Rivkin Ovarian Cancer Grant: 05/01/06-04/30/07, “Transglutaminase modulates resistance to chemotherapy in Ovarian Cancer”
Harikrishna Nakshatri, Ph.D.
- National Institutes of Health (R01 CA89153-01), AKT-mediated tamoxifen resistance in breast cancer cells. (1,173,375.00), 05/01/01 to 04/30/2007, Principal Investigator, 30% (under no cost extension)
- American Institute for Cancer Research. “The role of the herb feverfew in preventing CXCR4-mediated metastasis in breast cancer” 7/31/2003-12/31/2006, Principal Investigator, 5% (under no cost extension)
- Kentucky Lung Cancer Research Program. “Parthenolides as potential treatments for lung cancer” 3/1/2004 to 2/28/2006, Principal Investigator, 4%.
- Department of Defense. “A Mechanistic and in vivo evaluation of Dimethylaminoparthenolide, a new agent to treat prostate cancer” 12/15/2005 to 1/14/2009, Co-investigator, 10% Effort.
- Flight Attendant Medical Research Institute, “Developing DMAPT, A NF-KappaB Inhibitor for Bladder Cancer” 07/01/2006 to 6/30/2009, Principal Investigator, 20% Effort.
- Susan G. Komen Breast Cancer Foundation, “CXCR4: Wnt in Chemoresistance of Breast Cancer 05/01/2006 to 4/30/2008, Principal Investigator, 15% Effort.
- IU Cancer Center Pilot Project, “Identification of Invasive Breast Cancer Progenitor Cells 05/15/2006 to 05/14/2008, Principal Investigator, 2% Effort.
- DOD – BC053295, “Do microRNA’s Mediate Estrogen-Dependent Repression of Genes 07/01/2006 to 6/30/2007, Principal Investigator, 10% Effort.
- National Institutes of Health (1R03 CA123561-01), “Chemoprevention through activation of estrogen receptor alpha-induced senescence” 07/11/06 to 07/10/08, Principal Investigator, 5% Effort.
- IU-Purdue Cancer Center Pilot Project, “Identification of the Invasive/Metastatic Subpopulations of Breast Cancer Progenitor Cells” 8/15/06 to 7/31/07, Co-principal Investigator, 2% effort.
Louis M Pelus, Ph.D.
- NIH/NHLBI (1 R01 HL 079654-01), “Role of Survivin in blood stem cell cycle and apoptosisThe major goals of this project are to define the hematopoietic functions of Survivin in regulation of cell cycle and interactions with the p53 family of tumor suppressors.” Pelus-PI. (7/1/04 – 6/30/08)
- NIH/NHLBI (2 R01 HL 69669-05) “Chemokine induced hematopoietic stem cell mobilization” Pelus-PI (7/1/06 – 6/30/11)
David A. Potter, M.D., Ph.D.
Lawrence Quilliam, Ph.D.
Ann Roman, Ph.D.
Max Schmidt, M.D., Ph.D.
Martin L. Smith, Ph.D.
- American Institute for Cancer Research, 6/1/05-3/31/07
- U.S. Department of Defense, “Selenium potentiates chemotherapeutic selectivity: Improving efficacy and reducing toxicity” 3/1/06-2/28/08
Christopher Touloukian, M.D., Ph.D.
Gotz VonBulow, Ph.D.
Jian-Ting Zhang, Ph.D.
- National Institutes of Health (R01 CA120221): “Targeting the oligomerization of human ABCG2”, 2006-2010. Role: P.I. (15% effort)
- National Institutes of Health (R01 CA94961): “Role of p170 in tumorigenesis”, 2003-2008, Role: P.I. (20% effort)
- Department of Defense Prostate Cancer Research Program (W81XWH-05-1-0102): “The double-edged sword of prostate cancer: 14-3-3s”, 2004-2007. Role: P.I. (20% effort)
- National Institutes of Health (P30 CA82709): Cancer Center Support Grant. 1999-2008, P.I.: Stephen Williams; Role: Program co-leader (5% effort)
- Department of Defense Breast Cancer Research Program (W81XWH-04-1-0359): ” Functional form of breast cancer resistance protein”, 2004-2007. P.I.: Junkang Xu (predoctoral fellow)
Role: Mentor (no salary support)
- Department of Defense Breast Cancer Research Program (W81XWH-06-1-0490): “Fatty acid synthase: a novel target for treatment of drug resistant breast cancers”, 2006-2009. P.I.: Hailan Liu (predoctoral fellow) Role: Mentor (no salary support)
- Walther Cancer Institute: “Drug discovery using virtual screening/chemoinformatics for better treatment of refractory cancers” 2006-2007. Role: P.I. (no salary support)
- Indiana University Cancer Center Pilot Project: “Title: Discovery of 14-3-3s inhibitors for better treatment of pancreatic cancers using chemoinformatics/virtual screening” 2006-2007. Role: P.I. (no salary support)
|
